Novamind announces it will conduct a Phase II clinical trial for the sponsor, Usona Institute, on a psilocybin-based therapy for MDD.
Novamind announces it will conduct a Phase II clinical trial for the sponsor, Usona Institute, on a psilocybin-based therapy for MDD.
With a mental health catastrophe in the United States spiraling out of control, the Biden "plan" is just more of what has failed.
Seelos Therapeutics reports progress on several of its drug R&D initiatives, including preparing for a Phase IIb/Phase III trial of SLS-005 for ALS.
Field Trip Health announces a strategic partnership with Cerebral, "the fastest growing online mental health platform".
MindMed releases a peer-reviewed study that confirms the similar psychoactive effects of psilocybin and Lysergic Acid Diethylamide (LSD).
MINDCURE announces new formulations for its proprietary synthetic ibogaine, supported by a new patent application.
Revitalist and Pharmather to collaborate on novel and standardized treatment protocols for for ketamine-based psychotherapy.
Red Light Holland reports quarterly revenue growth of 28% and gross profit growth of 48% for Q3 of fiscal 2022. Strong cash position of CAD$27.3 million.
Mydecine prepares to submit its IND and application for Breakthrough Therapy Status for smoking cessation after successful meeting with FDA.
Novamind reports 32% q-o-q revenue growth, up to CAD $2.45 million in its latest quarter. Cash balance of ~CAD$8 million including post-period financing.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now